BuSpar patent appeal
Executive Summary
U.S. appeals court to hear oral arguments on BuSpar patent infringement lawsuit July 12. The court earlier denied Bristol-Myers Squibb's motion for a stay of the D.C. federal court's order to delist a BuSpar metabolite patent from the "Orange Book" and approve generic buspirone (1"The Pink Sheet" April 2, p. 28). Mylan filed suit against Bristol and FDA Nov. 30